Hans D Menssen1, Ulf Harnack2, Ulrike Erben3, Dario Neri4, Burkhard Hirsch5,6, Horst Dürkop7. 1. Division of Hematology and Oncology, Campus Benjamin Franklin, Department of Medicine, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. hans_dietrich.menssen@charite.de. 2. Division of Oncology and Hematology, Campus Mitte, Department of Medicine, Charité-Universitätsmedizin Berlin, Charité-Platz 1, 10117, Berlin, Germany. 3. Division of Gastroenterology, Infectious Diseases and Rheumatology, Medical Department, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. 4. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Wolfgang-Pauli-Str. 10, 8093, Zurich, Switzerland. 5. Department of Pathology at Campus Benjamin Franklin, Campus Mitte, Institute of Pathology, Charité-Universitätsmedizin Berlin, Virchowweg 15, 10117, Berlin, Germany. 6. Department of Medicine, Campus Mitte, Institute of Pathology, Charité-Universitätsmedizin Berlin, Virchowweg 15, 10117, Berlin, Germany. 7. Pathodiagnostik Berlin, Komturstrasse 58-62, 12099, Berlin, Germany.
Abstract
PURPOSE: To analyze the impact of TNFα or IL2 on human lymphocytes in vitro and the anti-tumor and immune-modifying effects of L19-IL2 and L19-TNFα on subcutaneously growing J558L myeloma in immunocompetent mice. METHODS: PBMCs from three healthy volunteers were incubated with IL2, TNFα, or with IL2 plus addition of TNFα (final 20 h). BALB/c J558L mice with subcutaneous tumors were treated with intravenous L19-TNFα plus L19-IL2, or controls. Tumor growth and intra- and peri-tumoral tissues were analyzed for micro-vessel density, necrosis, immune cell composition, and PD1 or PD-L1 expressing cells. RESULTS: Exposure of PBMC in vitro to IL2, TNFα, or to IL2 over 3 and 5 days plus TNFα for the final 20 h resulted in an approximately 50 and 75% reduction of the CD25low effector cell/CD25high Treg cell ratio, respectively, compared to medium control. IL2 or TNFα increased the proportion of CD4- CD25low effector lymphocytes while reducing the proportion of CD4+ CD25low Teff cells. In the J558L myeloma model, tumor eradication was observed in 58, 42, 25, and 0% of mice treated with L19-TNFα plus L19-IL2, L19-TNFα, L19-IL2, and PBS, respectively. L19-TNFα/L19-IL2 combination caused tumor necrosis, capillary density doubling, peri-tumoral T cell and PD1+ T cell reduction (- 50%), and an increase in PD-L1+ myeloma cells. CONCLUSION: IL2, TNFα, or IL2 plus TNFα (final 20 h) increased the proportion of CD4- CD25low effector lymphocytes possibly indicating immune activation. L19-TNFα/L19-IL2 combination therapy eradicated tumors in J558L myeloma BALB/c mice likely via TNFα-induced tumor necrosis and L19-TNFα/L19-IL2-mediated local cellular immune reactions.
PURPOSE: To analyze the impact of TNFα or IL2 on human lymphocytes in vitro and the anti-tumor and immune-modifying effects of L19-IL2 and L19-TNFα on subcutaneously growing J558L myeloma in immunocompetent mice. METHODS: PBMCs from three healthy volunteers were incubated with IL2, TNFα, or with IL2 plus addition of TNFα (final 20 h). BALB/c J558L mice with subcutaneous tumors were treated with intravenous L19-TNFα plus L19-IL2, or controls. Tumor growth and intra- and peri-tumoral tissues were analyzed for micro-vessel density, necrosis, immune cell composition, and PD1 or PD-L1 expressing cells. RESULTS: Exposure of PBMC in vitro to IL2, TNFα, or to IL2 over 3 and 5 days plus TNFα for the final 20 h resulted in an approximately 50 and 75% reduction of the CD25low effector cell/CD25high Treg cell ratio, respectively, compared to medium control. IL2 or TNFα increased the proportion of CD4- CD25low effector lymphocytes while reducing the proportion of CD4+ CD25low Teff cells. In the J558L myeloma model, tumor eradication was observed in 58, 42, 25, and 0% of mice treated with L19-TNFα plus L19-IL2, L19-TNFα, L19-IL2, and PBS, respectively. L19-TNFα/L19-IL2 combination caused tumor necrosis, capillary density doubling, peri-tumoral T cell and PD1+ T cell reduction (- 50%), and an increase in PD-L1+ myeloma cells. CONCLUSION:IL2, TNFα, or IL2 plus TNFα (final 20 h) increased the proportion of CD4- CD25low effector lymphocytes possibly indicating immune activation. L19-TNFα/L19-IL2 combination therapy eradicated tumors in J558L myeloma BALB/c mice likely via TNFα-induced tumor necrosis and L19-TNFα/L19-IL2-mediated local cellular immune reactions.
Authors: Maria Gavriatopoulou; Evangelos Terpos; Efstathios Kastritis; Meletios A Dimopoulos Journal: Expert Opin Drug Saf Date: 2017-01-11 Impact factor: 4.250
Authors: Kartik Sehgal; Rituparna Das; Lin Zhang; Rakesh Verma; Yanhong Deng; Mehmet Kocoglu; Juan Vasquez; Srinivas Koduru; Yan Ren; Maria Wang; Suzana Couto; Mike Breider; Donna Hansel; Stuart Seropian; Dennis Cooper; Anjan Thakurta; Xiaopan Yao; Kavita M Dhodapkar; Madhav V Dhodapkar Journal: Blood Date: 2015-04-13 Impact factor: 22.113
Authors: Balaji Balasa; Rui Yun; Nicole A Belmar; Melvin Fox; Debra T Chao; Michael D Robbins; Gary C Starling; Audie G Rice Journal: Cancer Immunol Immunother Date: 2014-10-07 Impact factor: 6.968
Authors: Stefania Gallo; Maria Vittoria Arcidiacono; Veronica Tisato; Roberta Piva; Letizia Penolazzi; Cristina Bosi; Carlo V Feo; Roberta Gafà; Paola Secchiero Journal: Onco Targets Ther Date: 2018-09-20 Impact factor: 4.147